comparemela.com

Latest Breaking News On - Participants with advanced solid tumors - Page 1 : comparemela.com

TAR-210 results show 90 percent recurrence-free survival

Updated results reinforce the potential of TAR-210 to transform treatment of non-muscle-invasive bladder cancer with fibroblast growth factor receptor.

Comunidad autonoma de catalunaRegion flamandeSan antonioUnited statesEurop urolJanssen pharmaceuticaTanakam sonpavdeClin pharmacolSabine brookmanHenar heviaIndianj urolAstex therapeuticsDrug administrationEuropean medicines agencyNone of janssen cilag internationalEuropean society for medical oncology

Johnson & Johnson Highlights Ambition to Transform the Treatment of Prostate Cancer and Bladder Cancer through Data Presentations at ASCO GU

/PRNewswire/ Johnson & Johnson announced today new clinical and real-world evidence data will be featured in 18 abstracts at this year s ASCO GU Symposium.

San franciscoUnited statesLuca dezzaniObrian kenneyKiran patelLaboratory abnormalitiesExchange commissionYork heart associationJanssen research developmentAstex pharmaceuticalsJanssen pharmaceuticalsClinical developmentNone of janssen research developmentEarly developmentData monitoring committeeEuropean medicines agency

U S Food and Drug Administration Grants Full Approval for BALVERSA® to Treat Locally Advanced or Metastatic Bladder Cancer with Select Genetic Alterations

/PRNewswire/ Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) for.

United statesKiran patelAnia diantonioAstex pharmaceuticalsAmerican cancer societyHealth professional versionNational cancer instituteDrug administrationJanssen biotech incAmerican society of clinical oncology annual meetingExchange commissionJanssen pharmaceuticalsNone of janssen research developmentJanssen pharmaceuticals incClinical developmentJanssen research development

Johnson & Johnson : Results from Phase 2 THOR-2 Study Show Improved Rates of Recurrence-Free Survival in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer with Select Fibroblast Growth Factor -October 23, 2023 at 07:22 am EDT

News Release Media Contacts: Suzanne Frost +1 416-317-0304 Brian Kenney +1 215-620-0111 .

United kingdomJames wf cattoIndianj urolClin urolObrian kenneyKiran patelJnjinnovmedand janssenExchange commissionDrug administrationClinical developmentCompanies of johnsonEuropean society for medical oncologyDepartment of oncologyEuropean society for medical oncology congressNone of janssen research developmentJanssen research development

First Results with Erdafitinib-Releasing Intravesical

Investigational TAR-210 first-in-human results highlight the potential for local sustained release of erdafitinib with a novel intravesical delivery.

Comunidad autonoma de catalunaRegion flamandeIndianj urolJanssen cilag gmbJanssen pharmaceuticaJeffrey infanteMartin vogelUrology care foundationJanssen research developmentNone of the janssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonEuropean society for medical oncologyAstex therapeuticsOncology early clinical developmentTranslational researchAstex announces new drug discovery alliance

vimarsana © 2020. All Rights Reserved.